A Systematic Review and a Meta-Analysis of the Yellow Fever Vaccine in the Elderly Population
We conducted a systematic review and a meta-analysis to assess the risk of serious adverse events in the elderly after yellow fever vaccination compared to the non-elderly population. We searched multiple databases and grey literature, and we selected research without language and publication date r...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-04-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/10/5/711 |
| _version_ | 1797494851906830336 |
|---|---|
| author | Ariane de Jesus Lopes de Abreu João Roberto Cavalcante Letícia Wigg de Araújo Lagos Rosângela Caetano José Ueleres Braga |
| author_facet | Ariane de Jesus Lopes de Abreu João Roberto Cavalcante Letícia Wigg de Araújo Lagos Rosângela Caetano José Ueleres Braga |
| author_sort | Ariane de Jesus Lopes de Abreu |
| collection | DOAJ |
| description | We conducted a systematic review and a meta-analysis to assess the risk of serious adverse events in the elderly after yellow fever vaccination compared to the non-elderly population. We searched multiple databases and grey literature, and we selected research without language and publication date restrictions. Studies were analyzed in a descriptive way and meta-analyzed and expressed in terms of prevalence ratio and risk ratio with a 95% confidence interval, depending on the degree of heterogeneity found. A total of 18 studies were included and 11 were meta-analyzed. The results obtained through the meta-analysis showed a risk of serious adverse events after yellow fever vaccination three times higher for the elderly when compared to the non-elderly population and five times higher for persons > 70 years. In relation to adverse event types, viscerotropic disease associated with the yellow fever vaccine had a risk that was six times higher when compared to the population < 60 years. The evidence found supports that the vaccine indication in individuals > 60 years of age should be based on a careful analysis of individual benefit-risk assessments. The results found suggest a higher risk of events for individuals > 70 years, especially for viscerotropic and neurotropic disease associated with YFV contraindicating the use of the YFV in this age group. |
| first_indexed | 2024-03-10T01:40:15Z |
| format | Article |
| id | doaj.art-48ef7765b7144c359ff2432cc2d66d51 |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-10T01:40:15Z |
| publishDate | 2022-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-48ef7765b7144c359ff2432cc2d66d512023-11-23T13:25:57ZengMDPI AGVaccines2076-393X2022-04-0110571110.3390/vaccines10050711A Systematic Review and a Meta-Analysis of the Yellow Fever Vaccine in the Elderly PopulationAriane de Jesus Lopes de Abreu0João Roberto Cavalcante1Letícia Wigg de Araújo Lagos2Rosângela Caetano3José Ueleres Braga4Instituto Nacional de Cardiologia, Rio de Janeiro 22240-006, BrazilInstituto de Medicina Social da Universidade do Estado do Rio de Janeiro, Rio de Janeiro 20550-013, BrazilInstituto Nacional de Cardiologia, Rio de Janeiro 22240-006, BrazilInstituto de Medicina Social da Universidade do Estado do Rio de Janeiro, Rio de Janeiro 20550-013, BrazilInstituto de Medicina Social da Universidade do Estado do Rio de Janeiro, Rio de Janeiro 20550-013, BrazilWe conducted a systematic review and a meta-analysis to assess the risk of serious adverse events in the elderly after yellow fever vaccination compared to the non-elderly population. We searched multiple databases and grey literature, and we selected research without language and publication date restrictions. Studies were analyzed in a descriptive way and meta-analyzed and expressed in terms of prevalence ratio and risk ratio with a 95% confidence interval, depending on the degree of heterogeneity found. A total of 18 studies were included and 11 were meta-analyzed. The results obtained through the meta-analysis showed a risk of serious adverse events after yellow fever vaccination three times higher for the elderly when compared to the non-elderly population and five times higher for persons > 70 years. In relation to adverse event types, viscerotropic disease associated with the yellow fever vaccine had a risk that was six times higher when compared to the population < 60 years. The evidence found supports that the vaccine indication in individuals > 60 years of age should be based on a careful analysis of individual benefit-risk assessments. The results found suggest a higher risk of events for individuals > 70 years, especially for viscerotropic and neurotropic disease associated with YFV contraindicating the use of the YFV in this age group.https://www.mdpi.com/2076-393X/10/5/711yellow fever vaccineadverse eventssystematic reviewaged |
| spellingShingle | Ariane de Jesus Lopes de Abreu João Roberto Cavalcante Letícia Wigg de Araújo Lagos Rosângela Caetano José Ueleres Braga A Systematic Review and a Meta-Analysis of the Yellow Fever Vaccine in the Elderly Population Vaccines yellow fever vaccine adverse events systematic review aged |
| title | A Systematic Review and a Meta-Analysis of the Yellow Fever Vaccine in the Elderly Population |
| title_full | A Systematic Review and a Meta-Analysis of the Yellow Fever Vaccine in the Elderly Population |
| title_fullStr | A Systematic Review and a Meta-Analysis of the Yellow Fever Vaccine in the Elderly Population |
| title_full_unstemmed | A Systematic Review and a Meta-Analysis of the Yellow Fever Vaccine in the Elderly Population |
| title_short | A Systematic Review and a Meta-Analysis of the Yellow Fever Vaccine in the Elderly Population |
| title_sort | systematic review and a meta analysis of the yellow fever vaccine in the elderly population |
| topic | yellow fever vaccine adverse events systematic review aged |
| url | https://www.mdpi.com/2076-393X/10/5/711 |
| work_keys_str_mv | AT arianedejesuslopesdeabreu asystematicreviewandametaanalysisoftheyellowfevervaccineintheelderlypopulation AT joaorobertocavalcante asystematicreviewandametaanalysisoftheyellowfevervaccineintheelderlypopulation AT leticiawiggdearaujolagos asystematicreviewandametaanalysisoftheyellowfevervaccineintheelderlypopulation AT rosangelacaetano asystematicreviewandametaanalysisoftheyellowfevervaccineintheelderlypopulation AT joseueleresbraga asystematicreviewandametaanalysisoftheyellowfevervaccineintheelderlypopulation AT arianedejesuslopesdeabreu systematicreviewandametaanalysisoftheyellowfevervaccineintheelderlypopulation AT joaorobertocavalcante systematicreviewandametaanalysisoftheyellowfevervaccineintheelderlypopulation AT leticiawiggdearaujolagos systematicreviewandametaanalysisoftheyellowfevervaccineintheelderlypopulation AT rosangelacaetano systematicreviewandametaanalysisoftheyellowfevervaccineintheelderlypopulation AT joseueleresbraga systematicreviewandametaanalysisoftheyellowfevervaccineintheelderlypopulation |